CPRX
Catalyst Pharmaceuticals, Inc.
$31.15
-0.05%
2026-05-08
About Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizure; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Key Fundamentals
P/E Ratio
18.54
Forward P/E
9.93
EPS (TTM)
$1.68
ROE
25.5%
Revenue Growth (YoY)
7.6%
Profit Margin
36.4%
Debt/Equity
0.29
Price/Book
4.00
Beta
0.72
Market Cap
$3.81B
Avg Volume (10D)
3.8M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$32.56
60D Low
$22.20
Avg Volume
1.7M
Latest Close
$31.15
Get breakout alerts for CPRX
Sign up for Breakout Scanner to receive daily notifications when CPRX triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Catalyst Pharmaceuticals, Inc. (CPRX) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors CPRX daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. CPRX operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.